No increased cardiovascular risk with febuxostat versus allopurinol
- PDF / 170,741 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 60 Downloads / 206 Views
1
No increased cardiovascular risk with febuxostat versus allopurinol There appears to be no increased risk of cardiovascular events in patients with gout receiving febuxostat compared with allopurinol, according to findings of the Menarini, Ipsen and Teijin Pharma-funded Febuxostat versus Allopurinol Streamlined Trial (FAST) study published in The Lancet.1 This non-inferiority study conducted in the UK, Denmark and Sweden compared the incidence of the composite of cardiovascular death or hospitalisation due to non-fatal myocardial infarction (MI), acute coronary syndrome or nonfatal stroke (primary cardiovascular endpoint) in 6128 patients with gout aged 60 years or over who were randomised to receive allopurinol or febuxostat at optimal dosages. Patients had a mean age of 71 years and received allopurinol prior to study entry; they had at least one additional cardiovascular risk factor but those with renal failure, severe congestive heart failure, or who had MI or stroke within the previous 6 months were excluded. Febuxostat was non-inferior to allopurinol with regard to the primary cardiovascular endpoint (n=172 vs 241 patients; 1.72 vs 2.05 events per 100 patient-years; adjusted hazard ratio [aHR] 0 85; 95% CI 0.70, 1.03; p
Data Loading...
